Pembrolizumab in Combination With Gemcitabine in People With Advanced MF or SS

Brief Summary: The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT04960618#contacts-and-locations

Sponsors: Memorial Sloan Kettering Cancer Center

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04960618

Recruiting

Participating Locations:

Memorial Sloan Kettering Cancer Center
New York, NY, United States
Contact
Alison Moskowitz, MD
moskowia@mskcc.org
646-608-3726
Recruiting
Columbia University Irving Medical Center
New York, NY, United States
Contact
Larisa Geskin, MD
212-305-5293
Recruiting